2016 American Transplant Congress
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.
Medicine/Nephrology and Hyeprtension, Weill Cornell Medical College, New York, NY.
BACKGROUND. The gut microbiome impacts drug absorption, metabolism, and distribution and was recently shown to be associated with tacrolimus dosing requirements. Since antibiotics can alter…2016 American Transplant Congress
Virological Response at 4 Weeks With a Sofosbuvir-Based Antiviral Regimen in Liver Transplant Recipients with Recurrent Hepatitis C.
Background: The literature is growing in the area of safety, efficacy and tolerability of sofosbuvir (SOF)- based antivirals therapy (AVT) in recurrent hepatitis C virus…2016 American Transplant Congress
Early Proteomic Predictors of Late Chronic Kidney Disease in Liver Transplant Recipients.
1Northwestern, Chicago; 2Baylor, Dallas.
Background: A high proportion of patients develop chronic kidney disease (CKD) after liver transplantation (LT). However, the ability to better select patients for nephroprotective interventions…2016 American Transplant Congress
Conversion from Tacrolimus to Belatacept in Pancreas Transplant Alone Recipients with Chronic Kidney Disease.
Medicine/Nephrology & Surgery/Transplant, Indiana University, Indianapolis.
Background: CNI toxicity is a well known risk factor for chronic kidney disease and ESRD in organ transplants. We report our experience in converting Pancreas…2016 American Transplant Congress
Calcineurin Inhibitors Promote Metastasis in Post-Transplant Colorectal Cancer Through Cancer Related- Exosomes Released from Cancer Cells in TGF Beta Independent Epitheilal to Mesenquimal Transition.
Introduction: Cancer is one of the major causes of death in kidney transplantation. Despite more mortality in colon cancer (CRC), similar incidence than general population…2016 American Transplant Congress
Early Conversion to Everolimus in De Novo Renal Transplant Recipients: Incidence of Viral Infections in the Randomized-Controlled ELEVATE Study.
BackgroundCytomegalovirus (CMV) and BK polyomavirus (BKPyV) infections are independent risk factors for acute rejection and graft loss. Early conversion from calcineurin inhibitors (CNIs) to everolimus…2015 American Transplant Congress
Incidence and Risk Factors of Contrast-Induced Nephropathy in Renal Allograft Recipients
University of Cincinnati, Cincinnati.
Background: Contrast-induced nephropathy (CIN) is associated with a significant increase in mortality and morbidity in patients with native kidneys. Data regarding CIN in renal allografts…2015 American Transplant Congress
Variants Associated With Tacrolimus Troughs in European American Kidney Transplant Recipients: A Genome Wide Association Study
Tacrolimus (tac) is dependent on CYP3A4/5 for metabolism. Variability in the metabolism is influenced by CYP3A5*3 alleles. This variant and clinical factors explain around 50%…2015 American Transplant Congress
Clinical Outcomes of Kidney Transplan Recipients After Sirolimus Or Everolimus Conversion. Experience in a Single Center
Transplant Unit, Fundación Valle del Lili, Cali, Colombia.
Introduction. The use of m_TOR inhibitors sirolimus (SRL) and everolimus (EVL), in kidney transplant recipients (KTR) is an alternative immunosuppressive therapy to reduce or withdrawal…2015 American Transplant Congress
Safety and Efficacy of Conversion from Conventional Twice Daily Tacrolimus to Once Daily Extended Release Tacrolimus in Stable Pancreas Transplant (SPK and PAK) Recipients
Surgery, Multi-Organ Transplant, Toronto General Hospital, Toronto, ON, Canada.
Background: A once-daily, modified-release oral formulation of tacrolimus has been developed to simplify dosing and improve medication adherence. There is limited data on the implementation…
American Transplant Congress abstracts